TP53 and cancer: The rationale for targeting CHK1 and other checkpoint kinases comes from the concept of cancer cell vulnerability to “checkpoint abrogation.” The genomic instability of cancer cells is mostly attributable to defects in the G1 checkpoint resulting from functional deficiency of the tumor suppressors p53 or Rb.